WELL Health: Scaling a High-Satisfaction, Tech-Enabled Outpatient Platform With Undervalued Operating Leverage

Haywood analyst Gianluca Tucci reiterated a Buy rating on WELL Health Technologies Corp yesterday and set a price target of C$8.50.

Gianluca Tucci has given his Buy rating due to a combination of factors that highlight WELL Health’s ability to scale profitably as a tech-enabled outpatient platform. He points to record Canadian patient volumes in 2025, strong organic visit growth, and evidence that the company’s digital tools are boosting throughput per provider rather than simply adding clinics or headcount.

He also emphasizes WELL’s exceptional patient satisfaction scores, which suggest durable demand, lower churn risk, and improved negotiating leverage with payors and partners. In addition, the continued expansion of its clinic footprint, especially in key provinces like Ontario and Alberta, reinforces a clear growth blueprint and supports his view that the market is undervaluing the operating leverage embedded in the model.

In another report released on February 18, Stifel Nicolaus also maintained a Buy rating on the stock with a C$9.00 price target.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WELL in relation to earlier this year.